3-(二甲氨基)-3-甲基丁烷-2-酮 | 56957-54-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3-(二甲氨基)-3-甲基丁烷-2-酮
• 英文名称: 2-N,N-dimethylamino-2-methylbutan-3-one
• 英文别名: 3-Dimethylamino-3-methyl-butanon-(2)；3-(Dimethylamino)-3-methylbutan-2-one
• CAS: 56957-54-1
• 化学式: C₇H₁₅NO
• 分子量: 129.202
• InChiKey: KEOMTUVWCHXGTD-UHFFFAOYSA-N

物化性质

• 沸点：
  72 °C(Press: 52 Torr)
• 密度：
  0.870±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(二甲氨基)-3-甲基丁烷-2-酮 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 生成 3-Dimethylamino-3-methyl-butanol-(2)
  参考文献：
  名称：

  Some Reactions of α-t-Acetylenic-t-amines¹

  摘要：

  DOI：

  10.1021/jo01063a023
• 作为产物：
  描述：

  (1,1-dimethylprop-2-ynyl)dimethylamine 在 硫酸 、 mercury(II) oxide 作用下， 以 甲醇 为溶剂， 生成 3-(二甲氨基)-3-甲基丁烷-2-酮
  参考文献：
  名称：

  Some Reactions of α-t-Acetylenic-t-amines¹

  摘要：

  DOI：

  10.1021/jo01063a023

文献信息

• Synthetic routes for a new family of chiral tetradentate ligands containing pyridine rings
  作者：Mathias Düggeli、Catherine Goujon-Ginglinger、Sarah Richard Ducotterd、David Mauron、Christophe Bonte、Alexander von Zelewsky、Helen Stoeckli-Evans、Antonia Neels

  DOI：10.1039/b210625f

  日期：——

  A series of new tetradentate ligands containing two bipyridine groups or two pyridine moieties carrying amine substituents has been synthesised either from 5'- and 6'-substituted chiral bipyridines, or from chiral pyridine derivatives. These precursors have been prepared from (-)-alpha-pinene or (-)-myrtenal, respectively. The structures of three tetradentate-, and of five chiral bipyridine ligands

  由5'-和6'-取代的手性联吡啶或由手性吡啶衍生物合成了一系列含有两个联吡啶基团或两个带有胺取代基的吡啶部分的新四齿配体。这些前体分别由（-）-α-pine烯或（-）-myrtenal制备。通过X射线衍射测定了三个四齿-和五个手性联吡啶配体的结构。
• TRIPEPTIDE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF
  申请人：NORTHWEST UNIVERSITY

  公开号：US20170267718A1

  公开（公告）日：2017-09-21

  Provided are a tripeptide compound, a preparation method therefor, and an application thereof. The structure of the related compound is represented by formula (I). The provided compound has angiotensin converting enzyme inhibiting bioactivity, and the compound and a pharmaceutical composition thereof play a role in preventing and treating hypertension and other cardiocerebral vascular system diseases.

  提供了一种三肽化合物，其制备方法和应用。相关化合物的结构由式（I）表示。提供的化合物具有抑制血管紧张素转换酶的生物活性，该化合物及其药物组成对预防和治疗高血压和其他心脑血管系统疾病起着作用。
• Substituted Oxindole Derivatives, Medicaments Containing Said Derivatives and Use Thereof
  申请人：Lubisch Wilfried

  公开号：US20120115842A1

  公开（公告）日：2012-05-10

  The invention relates to novel oxindole derivatives of general formula (I), wherein substituents A, B, X and Y are defined as in claim 1 , medicaments containing said derivatives, and the use thereof in the prophylaxis and/or treatment of vasopressin-dependent and/or oxytocin-dependent diseases.

  该发明涉及一种一般式（I）的新型氧吲哚衍生物，其中取代基A、B、X和Y的定义如权利要求书中，包含该衍生物的药物，以及在预防和/或治疗依赖于加压素和/或催产素的疾病中的使用。
• Pyrrolopyridine kinase inhibiting compounds
  申请人：Dong Han-Qing

  公开号：US20070129364A1

  公开（公告）日：2007-06-07

  Compounds represented by Formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, are inhibitors of least one of the Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mek1, PDK-1, GSK3β, EGFR, p70S6K, BMX, SGK, CaMKII, Tie-2, IGF-1R, Ron, Met, and KDR kinases in animals, including humans, for the treatment and/or prevention of various diseases and conditions such as cancer.

  由式（I）表示的化合物或其立体异构体或其药用可接受的盐，是对动物中至少一种Abl、Aurora-A、Blk、c-Raf、cSRC、Src、PRK2、FGFR3、Flt3、Lck、Mek1、PDK-1、GSK3β、EGFR、p70S6K、BMX、SGK、CaMKII、Tie-2、IGF-1R、Ron、Met和KDR激酶的抑制剂，包括人类，用于治疗和/或预防癌症等各种疾病和病况。
• HIGH PENETRATION PRODRUG COMPOSITIONS OF PEPTIDES AND PEPTIDE-RELATED COMPOUNDS
  申请人：Yu Chongxi

  公开号：US20090311184A1

  公开（公告）日：2009-12-17

  The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of peptides and peptide-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.

  本发明提供了新型高渗透性肽和肽相关化合物的组合物，即高渗透性前药（HPP）或高渗透性前药（HPP），能够以高渗透效率穿越生物屏障。 HPP能够在穿越生物屏障后转化为父活性药物或药物代谢物，从而可以治疗父药物或代谢物可以治疗的疾病。此外，HPP能够到达父药物可能无法访问或在目标区域提供足够浓度的区域，从而提供新的治疗方法。 HPP可以通过各种给药途径给予受试者，例如在高浓度下局部给药于病情的作用部位，或系统地给予生物学受体并以更快的速率进入循环系统。